INVICTA

Invicta Diagnostic Limited

Listed company · ISIN INE0XJ501010 · NSE SM · FV ₹10
Last price
₹67
-1.41%today
What this company does

Invicta Diagnostic Limited is a listed company. It booked ₹15 cr of revenue in its latest half year (H2 FY26) and kept 5.9% of sales as profit.

53out of 100
Equitytale Health Score
Mixed

Healthier than 53% of listed companies we score, on the 5 of 6 measures we could read for it. Each measure is ranked against the 2,334–2,885 companies that reported it.

Measures financial condition, not whether to buy. Learn what this score means · How this is calculated

Price momentum
neutral
RSI (14)
48

At close. Not part of the score.

Profitability & returns28

How much profit it earns on the money it employs

Balance sheet78

How much it owes, and whether earnings cover the interest

Cash quality41

Whether reported profit actually arrives as cash

Valuation39

What today's price implies, against our models or its peers

Governance & risk100

How much of the promoters' stake is pledged, and how much they hold · highest in its sector on what we could measure

Not measurable for this company: growth & consistency. Those pillars are left out of the score rather than counted as zero.

Is this company doing well?
not investment advice
A mixed picture
Strengths
✓ Makes a profit
✓ Promoters hold 67%
✓ No promoter shares pledged
✓ Virtually debt-free
Watch-outs
! Thin 5.9% net margin
! Low 3.6% return on equity

What if I invest in INVICTA?

Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.

You would put in
₹12.00 lakh
120 instalments
At 10% a year, it would become
₹20.15 lakh

The starting rate is a round number, not a view on this company — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.

Key ratios · latest half year + price
₹67▼ -1.41%
latest close · 2026-10-01
52-wk low ₹6444 sessions so far52-wk high ₹80
Is it cheap or expensive?
What you pay for the profits, book value and cash flow. Higher isn't automatically worse — it can signal faster growth.
P/E ratio42.1High
LowAverageHigh
P/B ratio1.68Moderate
Below bookModerateHigh
EV / EBITDA9.2Average
LowAverageHigh
How good is the business?
How much profit it earns from its money and its sales.
Return on equity3.6%Weak
WeakFairStrong ▸15%
Return on capital6.3%Weak
WeakFairStrong
Net margin5.9%Decent
ThinDecentStrong
EBITDA margin23.1%Healthy
ThinDecentHealthy
Is it financially safe?
How much it owes, and whether it can comfortably cover it.
Debt to equity0.07Comfortable
LowModerateHigh ▸1
Interest cover18.0×Strong
RiskyOkayStrong ▸5×
Current ratio4.79Ample
Tight ◂1HealthyAmple
More figures
Market cap
₹84 cr
Book value
₹40
EPS
₹0.79
latest half year
Net debt
₹-19 cr
more cash than debt
Enterprise value
₹65 cr
EBITDA
₹7 cr
annualised
EBIT
₹3 cr
annualised
Operating margin
10.9%
Return on assets
3.0%
Earnings yield
2.37%
P/S
2.72
Sales / share
₹24.5
Tax rate
50.1%
Face value
₹10
Shares
1.3 cr
Working capital
₹27 cr
Current assets
₹34 cr
Current liabilities
₹7 cr
Delivery %
76.3%
Strong / safeFairWeak / riskyValuation — a level, not good/badBands are general rules of thumb, not advice.

P/E, ROE, ROCE and margins are annualised from the latest half year; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-10-01.

Worth vs price · from the exchange filings
not investment advice
Hard to value confidentlyLow confidence
Too few reliable models — the filings don't support two independent estimates of value.
Models span ₹23–₹23, midpoint ₹23

An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.

P&L · H2 FY26 (consolidated)
Revenue from Operations₹15 cr
Other Income₹55.6 L
Total Income₹16 cr
Cost of Materials₹0 cr
Purchases of Stock-in-Trade₹1 cr
Inventory Change (±)₹-3.2 L
Employee Benefit Expense₹3 cr
Finance Costs₹9.3 L
Depreciation & Amortisation₹2 cr
Other Expenses₹8 cr
Total Expenses₹14 cr
Profit before Tax₹2 cr
Tax Expense₹79.1 L
Net Profit₹78.9 L
Net margin on total income4.9%
Where the money goes · H2 FY26
% of total income
Materials + stock-in-trade₹1 cr8.6%
Employee benefit expense₹3 cr19.8%
Finance costs₹9.3 L0.6%
Depreciation & amortisation₹2 cr11.8%
Other expenses₹8 cr49.3%
Tax expense₹79.1 L5.0%
Profit for the period₹78.9 L4.9%
Total income ₹16 cradds up to ₹100 ✓
Balance sheet & cash flow · as of Mar 2026
Low debt
Total assets
₹60 cr
Shareholder equity
₹50 cr
parent shareholders
Total debt
₹4 cr
Cash
₹22 cr
Who owns it · 2026-03-31
No pledge
Promoter
66.7%
FII / Foreign
4.2%
DII / Domestic
4.3%
Retail / others
24.8%
Smart-money activity
Bulk / block deals
SoldPINE OAK GLOBAL FUND · NSE1.94 L @ ₹73.795 Aug 26
BoughtBIRCHWOOD MULTI STGY FND OPENENDED PCC LTD - BIRCHWOOD GLOBAL ALPHA FUND · NSE1.94 L @ ₹73.795 Aug 26
What shareholders were asked to approve

A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.

Yearly shareholder meeting · 19 Sep 2026
See the official result
1
To consider and adopt (a) the Audited Standalone Financial Statements of the Company for the financial year ended March 31, 2026 and the reports of the Board of Directors and Auditors thereon; and (b) the Audited Consolidated Financial Statements of the Company for the financial year ended March 31, 2026 and the report of Auditors thereon
Backed by 100% of shareholders other than promotersneeded 50%
1.73 L votes for, 0 against
2
To appoint a director in place of Mr. Ketan Jayantilal Jain (DIN: 07819226), who retires by rotation and, being eligible, seeks re-appointment
Backed by 100% of shareholders other than promotersneeded 50%
1.73 L votes for, 0 against
3
Appointment of M/s Shrenik Nagaonkar & Associates, Company Secretaries as Secretarial Auditor of the Company
Backed by 100% of shareholders other than promotersneeded 50%
1.73 L votes for, 0 against
4
Appointment of Mr. Sanket Vinod Jain (DIN: 08299039) as Managing Director of the Company
Backed by 100% of shareholders other than promotersneeded 50%
1.73 L votes for, 0 against

Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.

Who controls this company, and what it pays them

Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.

The promoter group — 97 named members
owning 66.7% between them · as of 2026-03-31
BADAL KAILASH NAREDI11.07%
ROHIT PRAKASH SRIVASTAVA11.07%
SANKET VINOD JAIN10.47%
JAYESH PRAKASH JAIN7.93%
MONAL KETAN JAIN7.17%
DIPIKA JAYANTILAL JAIN4.76%
AMOL PURUSHOTTAM KHANDELWAL4.03%
KUSHAL WAYUNANDAN KOLI2.15%

Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.

Money it raised, and what it did with it

When a company raises money from investors, it has to say up front what the money is for. The rules then make it report, every three months until the money is gone, how much of each of those things it has actually paid for — so a promise made while asking for the money can be checked afterwards.

₹28 cr raised in Dec 2025 by selling shares to the public

As of Mar 2026, the company says it has spent 26% of what it set aside, leaving ₹21 cr still to be spent.

Issue related Expenses
95%
₹3 cr of ₹3 cr
Funding capital expenditure for purchase of medical equipment towards establishment of five new diagnostic centres in Maharashtra
11%
₹2 cr of ₹21 cr
General Corporate purposes
58%
₹2 cr of ₹4 cr

Every figure above is taken from the statement the company files with the stock exchange each quarter, for as long as money it has raised remains unspent. The only thing we work out is how much of each stated purpose has been paid for — one number divided by another from the same filing. Whether a plan that changed was a good change is not something a filing can tell you. See the filing

How the stock has moved · adjusted for splits & bonuses
Data from primary exchange filings · analysis tool, not investment advice.